Insights from the ground up with the 2019 Emerging Markets BCI survey
In the global competition for biopharmaceutical investment policy environments either enable or hinder an economy’s capacity to compete. Today who is winning this race and who is trailing? What aspects of individual economies’ environments are providing momentum and what is holding them back? And ultimately, how can governments improve their competitiveness and secure a larger piece of global biomedical investment?
Read more at: News Room
